Key Takeaways Roche announced plans to acquire Poseida Therapeutics for about $1 billion. Merck, AstraZeneca and Novartis ...

The outcome marks the latest setback for the company's Phase 3 SKYSCRAPER-01 study, which evaluated tiragolumab in combination with Roche's (OTCQX:RHHBY) cancer immunotherapy Tecentriq against ...

PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on RHHBY: Roche NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

(RTTNews) - Roche (RHHBY) announced that the U.S. Food and ... Roche NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Barclays says Roche’s (RHHBY) SKY-01 failure is not totally unexpected ... TIGIT in lung cancer is likely already priced into the stock, the analyst tells investors in a research note.

Roche’s (OTC:RHHBY) member Genentech, announced interim results from a phase III study evaluating Tecentriq and Avastin plus chemotherapy for first-line treatment of... ByZacks Investment ...